Marshall Wace
ANIX icon

Marshall Wace’s Anixa Biosciences ANIX Stock Holding History

Marshall Wace’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$919K Buy
328,332
+155,153
+90% +$431K ﹤0.01% 2236
2026
Q1 		$447K Buy
173,179
+132,621
+327% +$393K ﹤0.01% 2499
2025
Q4 		$127K Sell
40,558
-22,159
-35% -$90.7K ﹤0.01% 2677
2025
Q3 		$207K Buy
62,717
+50,995
+435% +$161K ﹤0.01% 2563
2025
Q2 		$38.7K Buy
+11,722
New +$33.5K ﹤0.01% 2612
2024
Q4 		– Sell
-44,483
Closed -$140K – 2555
2024
Q3 		$140K Buy
+44,483
New +$137K ﹤0.01% 2340
2024
Q2 		– Sell
-26,372
Closed -$82.3K – 2512
2024
Q1 		$82.3K Buy
26,372
+15,697
+147% +$62.6K ﹤0.01% 2322
2023
Q4 		$41.4K Buy
+10,675
New +$36K ﹤0.01% 2084
2022
Q2 		– Sell
-28,923
Closed -$80K – 3391
2022
Q1 		$80K Sell
28,923
-13,050
-31% -$38.3K ﹤0.01% 3216
2021
Q4 		$125K Hold
41,973
– – ﹤0.01% 3325
2021
Q3 		$200K Buy
+41,973
New +$189K ﹤0.01% 2803

Other funds holding ANIX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $5.21B AUM 31.48% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Marshall Wace's ANIX Position: Q2 2026 in Review

Marshall Wace increased its Anixa Biosciences (ANIX) stake by 90% in Q2 2026, buying an estimated $431K and bringing the position to 328,332 shares worth $919K. The position accounts for ﹤0.01% of the portfolio, ranked #2236.

Marshall Wace first reported a position in ANIX in Q3 2021 and has held it in 11 quarters since. 62 funds tracked by Wall St. Rank hold ANIX as of Q2 2026.

  • Marshall Wace held 328,332 shares of Anixa Biosciences worth $919K as of Q2 2026.
  • Marshall Wace bought 155,153 Anixa Biosciences shares in Q2 2026, an estimated $431K.
  • Anixa Biosciences made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2236 holding.
  • Marshall Wace first reported a position in Anixa Biosciences in Q3 2021 and has held it in 11 quarters since.
  • 62 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.